
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The FDA issued an approvable letter for a sustained-release formulation of doxazosin mesylate (Cardura XL), an alpha-blocker used to treat BPH.





